• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.08% Nasdaq Down0.69%

    Myriad Genetics, Inc. (MYGN)

    39.09 Up 0.58(1.51%) 4:00PM EDT
    |After Hours : 38.51 Down 0.58 (1.48%) 4:41PM EDT
    ProfileGet Profile for:
    Myriad Genetics, Inc.
    320 Wakara Way
    Salt Lake City, UT 84108
    United States - Map
    Phone: 801-584-3600
    Fax: 801-584-3640
    Website: http://www.myriad.com

    Index Membership:N/A
    Industry:Research Services
    Full Time Employees:2,038

    Business Summary 

    Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, diagnose disease, assess the risk of disease progression, and guide treatment decisions across six medical specialties where molecular diagnostics can enhance patient care and lower healthcare costs. Its various molecular diagnostic tests include myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; BRACAnalysis and BART, sequencing tests for hereditary breast and ovarian cancer; BRACAnalysis CDx sequencing test for use as a companion diagnostic in identifying ovarian cancer patients with deleterious suspected deleterious germline; and Tumor BRACAnalysis CDx sequencing test used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS sequencing test for colorectal and uterine cancer; COLARIS AP sequencing test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, an RNA expression test for prostate cancer; EndoPredict expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; and myPlan lung cancer, an RNA expression test for lung cancer. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

    Key Statistics

    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on Myriad Genetics, Inc.

    Corporate Governance 
    Myriad Genetics, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 5. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 7; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Mark Christopher Capone , 53
    Chief Exec. Officer and Pres
    Dr. Walter A. Gilbert Ph.D., 83
    Founding Scientist, Vice Chairman and Member of Compensation Committee
    Dr. Jerry S. Lanchbury Ph.D., 56
    Chief Scientific Officer
    Mr. Richard M. Marsh Esq., 57
    Exec. VP, Gen. Counsel and Sec.
    Dr. Peter D. Meldrum Ph.D., 68
    Mr. R. Bryan Riggsbee ,
    Chief Financial Officer, Exec. VP and Treasurer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders